In a new study, researchers found that men with stable coronary artery disease who are on Viagra due to impotence may live longer and have a lower risk of a heart attack.
The research was conducted by a team from Karolinska Institutet in Sweden.
Impotence can be an early warning sign of heart disease in healthy men and is treated either locally with alprostadil, which dilates the blood vessels so that the penis stiffens, or with so-called PDE5 inhibitors, such as Viagra or Cialis.
Viagra is taken in tablet form orally before sex, inhibiting the enzyme phosphodiesterase5 (PDE5) in the penis to increase the blood flow.
Since PDE5 inhibitors decrease blood pressure, they were previously not recommended for men with coronary artery disease due to the risk of a heart attack.
However, in 2017 the team showed that men who have had a heart attack tolerate the drug well and that it even prolongs life expectancy and protects against new infarctions and heart failure.
In the current study, the researchers sought to compare the effect of alprostadil and PDE5 inhibitors in men with stable coronary artery disease.
The patients were to have had either an infarction, balloon dilation or coronary artery bypass surgery at least six months before the onset of treatment for erectile dysfunction.
The registry study comprised 16,500 men treated with PDE5 inhibitors and just under 2,000 who received alprostadil. The data was collected from the patient, drug and cause of death registries.
The team found that the men who received PDE5 inhibitors lived longer and had a lower risk of new heart attack, heart failure, balloon dilation and bypass surgery than those who received alprostadil.
The protection was dose-dependent, so that the more frequent the dose of PDE5 inhibitor, the lower the risk.
This suggests that there’s a causal link. It is possible that those who received PDE5 inhibitors were healthier than those on alprostadil and therefore had a lower risk.
To ascertain whether it is the drug that reduces the risk, the team would need to randomly assign patients to two groups, one that takes PDE5 and one that doesn’t.
As PDE5 inhibitors are available by prescription only in Sweden, they cannot be bought over the counter, but the team hopes that men with coronary artery disease do not shy away from addressing the matter with their doctor.
The study is published in the Journal of the American College of Cardiology. One author of the study is Martin Holzmann.
Copyright © 2021 Knowridge Science Report. All rights reserved.
